Clinical trial of a humanized monoclonal anti-IL15Rβ (CD122), in HTLV-1 associated myelopathy/ tropical spastic paraparesis (HAM/TSP)

R. Massoud,Yoshimi Enose-Akahata,Giovanna S. Manzano (Brunetto),J. Ohayon,Kaylan Fenton,I. Cortese,T. Waldmann,S. Jacobson

DOI: https://doi.org/10.1186/1742-4690-11-S1-O6

2014-01-07

Retrovirology

Abstract:

What problem does this paper attempt to address?

Impact of Antihypertensive Medication Changes After Renal Denervation Among Different Patient Groups: SPYRAL HTN-ON MED

Raymond R. Townsend,Keith C. Ferdinand,David E. Kandzari,Kazuomi Kario,Felix Mahfoud,Michael A. Weber,Roland E. Schmieder,Stuart Pocock,Konstantinos Tsioufis,Shukri David,Susan Steigerwalt,Antony Walton,Ingrid Hopper,Barry Bertolet,Faisal Sharif,Karl Fengler,Martin Fahy,Douglas A. Hettrick,Sandeep Brar,Michael Böhm

DOI: https://doi.org/10.1161/hypertensionaha.123.22251

IF: 9.8968

2024-02-07

Hypertension

Abstract:Hypertension, Ahead of Print. BACKGROUND:The SPYRAL HTN-ON MED trial showed significant office and nighttime systolic blood pressure (BP) reductions in patients with hypertension following renal denervation (RDN) compared with sham-control patients, despite similar 24-hour BP reductions. We compared antihypertensive medication and BP changes among prespecified subpopulations.METHODS:The multicenter, randomized, sham-controlled, blinded SPYRAL HTN-ON MED trial (n=337) evaluated BP changes after RDN compared with a sham procedure in patients with hypertension prescribed 1 to 3 antihypertensive drugs. Most patients (n=187; 54%) were enrolled outside the United States, while 156 (46%) US patients were enrolled, including 60 (18%) Black Americans.RESULTS:Changes in detected antihypertensive drugs were similar between RDN and sham group patients in the outside US cohort, while drug increases were significantly more common in the US sham group compared with the RDN group. Patients from outside the United States showed significant reductions in office and 24-hour mean systolic BP at 6 months compared with the sham group, whereas BP changes were similar between RDN and sham in the US cohort. Within the US patient cohort, Black Americans in the sham control group had significant increases in medication burden from baseline through 6 months (P=0.003) but not in the RDN group (P=0.44).CONCLUSIONS:Patients enrolled outside the United States had minimal antihypertensive medication changes between treatment groups and had significant office and 24-hour BP reductions compared with the sham group. Increased antihypertensive drug burden in the US sham cohort, especially among Black Americans, may have diluted the treatment effect in the combined trial population.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT02439775.

peripheral vascular disease
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials

Ajay J Kirtane,Andrew S P Sharp,Felix Mahfoud,Naomi D L Fisher,Roland E Schmieder,Joost Daemen,Melvin D Lobo,Philipp Lurz,Jan Basile,Michael J Bloch,Michael A Weber,Manish Saxena,Yale Wang,Kintur Sanghvi,J Stephen Jenkins,Chandan Devireddy,Florian Rader,Philippe Gosse,Marc Sapoval,Neil C Barman,Lisa Claude,Dimitri Augustin,Lisa Thackeray,Christopher M Mullin,Michel Azizi,RADIANCE Investigators and Collaborators

DOI: https://doi.org/10.1001/jamacardio.2023.0338

2023-05-01

Abstract:Importance: Ultrasound renal denervation (uRDN) was shown to lower blood pressure (BP) in patients with uncontrolled hypertension (HTN). Establishing the magnitude and consistency of the uRDN effect across the HTN spectrum is clinically important. Objective: To characterize the effectiveness and safety of uRDN vs a sham procedure from individual patient-level pooled data across uRDN trials including either patients with mild to moderate HTN on a background of no medications or with HTN resistant to standardized triple-combination therapy. Data sources: A Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN SOLO and TRIO) and A Study of the ReCor Medical Paradise System in Stage II Hypertension (RADIANCE II) trials. Study selection: Trials with similar designs, standardized operational implementation (medication standardization and blinding of both patients and physicians to treatment assignment), and follow-up. Data extraction and synthesis: Pooled analysis using individual patient-level data using linear regression models to compare uRDN with sham across the trials. Main outcomes and measures: The primary outcome was baseline-adjusted change in 2-month daytime ambulatory systolic BP (dASBP) between groups. Results: A total of 506 patients were randomized in the 3 studies (uRDN, 293; sham, 213; mean [SD] age, 54.1 [9.3]; 354 male [70.0%]). After a 1-month medication stabilization period, dASBP was similar between the groups (mean [SD], uRDN, 150.3 [9.2] mm Hg; sham, 150.8 [10.5] mm Hg). At 2 months, dASBP decreased by 8.5 mm Hg to mean (SD) 141.8 (13.8) mm Hg among patients treated with uRDN and by 2.9 mm Hg to 147.9 (14.6) mm Hg among patients treated with a sham procedure (mean difference, -5.9; 95% CI, -8.1 to -3.8 mm Hg; P < .001 in favor of uRDN). BP decreases from baseline with uRDN vs sham were consistent across trials and across BP parameters (office SBP: -10.4 mm Hg vs -3.4 mm Hg; mean difference, -6.4 mm Hg; 95% CI, -9.1 to -3.6 mm Hg; home SBP: -8.4 mm Hg vs -1.4 mm Hg; mean difference, -6.8 mm Hg; 95% CI, -8.7 to -4.9 mm Hg, respectively). The BP reductions with uRDN vs sham were consistent across prespecified subgroups. Independent predictors of a larger BP response to uRDN were higher baseline BP and heart rate and the presence of orthostatic hypertension. No differences in early safety end points were observed between groups. Conclusions and relevance: Results of this patient-level pooled analysis suggest that BP reductions with uRDN were consistent across HTN severity in sham-controlled trials designed with a 2-month primary end point to standardize medications across randomized groups. Trial registration: ClinicalTrials.gov Identifier: NCT02649426 and NCT03614260.
Effects of catheter-based renal denervation in hypertension: a systematic review and meta-analysis

Davor Vukadinović,Lucas Lauder,David E. Kandzari,Deepak L Bhatt,Ajay J. Kirtane,Elazer R. Edelman,Roland Schmieder,Michel Azizi,Michael Bohm,Felix Mahfoud

DOI: https://doi.org/10.1101/2024.06.12.24308869

2024-06-17

Abstract:Background: Several sham-controlled trials have investigated the efficacy and safety of catheter-based renal denervation (RDN) with mixed outcomes. Aim: To perform a comprehensive meta-analysis of all randomized, sham-controlled trials investigating RDN with first- and second-generation devices in hypertension. Methods: We searched MEDLINE and Cochrane Library for eligible trials. Outcomes included both efficacy (24-hour and office systolic [SBP] and diastolic blood pressure [DBP]) and safety (all-cause death, vascular complication, renal artery stenosis >70%, hypertensive crisis) of RDN. We performed a study-level, pairwise, random-effects meta-analysis of the summary data. Results: Ten trials comprising 2,478 patients with hypertension while being either off- or on-treatment were included. Compared with sham, RDN reduced 24-hour and office systolic BP by 4.4 mmHg (95%CI -6.1, -2.7, p<0.00001) and 6.6 mmHg (95%CI -9.7, -3.6, p<0.0001), respectively. The 24-hour and office diastolic BP paralleled these findings (-2.6 mmHg, 95%CI -3.6, -1.5, p<0.00001; -3.5 mmHg, 95%CI -5.4, -1.6, p=0.0003). There was no difference in 24-hour and office SBP reduction between trials with and without concomitant antihypertensive medication (p for interaction 0.62 and 0.73, respectively). There was no relevant difference concerning vascular complications (OR 1.69, 95%CI 0.57-5.0, p=0.34), renal artery stenosis (OR 1.50, 95%CI 0.06-36.97, p=0.80), hypertensive crisis (OR 0.65, 95%CI 0.30-1.38, p=0.26) and all-cause death (OR 1.76, 95%CI 0.34-9.20, p=0.50) between RDN and sham groups. Change of renal function based on eGFR was comparable between groups (p for interaction 0.84). There was significant heterogeneity between trials. Conclusions: RDN safely reduces ambulatory and office SBP/DBP vs. a sham procedure in the presence and absence of antihypertensive medication.
Effects of renal denervation on blood pressure in patients with hypertension: a latest systematic review and meta-analysis of randomized sham-controlled trials

Yukako Ogoyama,Makiko Abe,Keisuke Okamura,Kazuhiro Tada,Kenichi Katsurada,Shigeru Shibata,Hisashi Kai,Hiromi Rakugi,Koichi Node,Hiroyoshi Yokoi,Kazuomi Kario,Hisatomi Arima

DOI: https://doi.org/10.1038/s41440-024-01739-y

2024-06-04

Hypertension Research

Abstract:The efficacy of renal denervation (RDN) has been controversial, but recent randomized sham-controlled trials demonstrated significant blood pressure reductions after RDN in patients with hypertension. We conducted a systematic review and updated meta-analysis to evaluate the effects of RDN on ambulatory and office blood pressures in patients with hypertension. Databases were searched up to 15 November 2023 to identify randomized, sham-controlled trials of RDN. The primary endpoint was change in 24 h ambulatory systolic blood pressure (SBP) with RDN versus sham control. The secondary endpoints were changes in 24 h ambulatory diastolic blood pressure, daytime and nighttime blood pressure (BP), office BP, and home BP. A sub-analysis determined outcomes by medication, procedure, and device. From twelve trials, 2222 patients with hypertension were randomized to undergo RDN ( n = 1295) or a sham procedure ( n = 927). At 2–6 months after treatment, RDN significantly reduced 24 h ambulatory SBP by 2.81 mmHg (95% confidence interval: −4.09, −1.53; p < 0.001) compared with the sham procedure. RDN also reduced daytime SBP by 3.17 mmHg (− 4.75, − 1.58; p < 0.001), nighttime SBP by 3.41 mmHg (− 4.69, − 2.13; p < 0.001), office SBP by 4.95 mmHg (− 6.37, − 3.54; p < 0.001), and home SBP by 4.64 mmHg (– 7.44, − 1.84; p = 0.001) versus the sham control group. There were no significant differences in the magnitude of BP reduction between first- and second-generation trials, between devices, or between with or without medication. These data from randomized sham-controlled trials showed that RDN significantly reduced all blood pressure metrics in medicated or unmedicated patients with hypertension, including resistant/uncontrolled hypertension.

peripheral vascular disease
Efficacy and Safety of Renal Denervation for Chinese Patients with Resistant Hypertension Using a Microirrigated Catheter: Study Design and Protocol for a Prospective Multicentre Randomised Controlled Trial

Zongjun Liu,Li Shen,Weijian Huang,Xianxian Zhao,Weiyi Fang,Changqian Wang,Zhaofang Yin,Jianan Wang,Guosheng Fu,Xuebo Liu,Jianjun Jiang,Zhihui Zhang,Jingbo Li,Yingmin Lu,Junbo Ge

DOI: https://doi.org/10.1136/bmjopen-2016-015672

IF: 3.006

2017-01-01

BMJ Open

Abstract:IntroductionAvailable data show that approximately 8%–18% of patients with primary hypertension will develop resistant hypertension. In recent years, catheter-based renal denervation (RDN) has emerged as a potential treatment option for resistant hypertension. A number of observational studies and randomised controlled trials among non-Chinese patients have demonstrated its potential safety and efficacy.Methods and analysisThis is a multicentre, randomised, open-label, parallel-group, active controlled trial that will investigate the efficacy and safety of a 5F saline-irrigated radiofrequency ablation (RFA) used for RDN in the treatment of Chinese patients with resistant hypertension. A total of 254 patients who have failed pharmacological therapy will be enrolled. Eligible subjects will be randomised in a 1:1 ratio to undergo RDN using the RFA plus antihypertensive medication or to receive treatment with antihypertensive medication alone. The primary outcome measure is the change in 24 hours average ambulatory systolic blood pressure from baseline to 3 months, comparing the RDN-plus-medication group with the medication-alone group. Important secondary endpoints include the change in office blood pressure from baseline to 6 months after randomisation. Safety endpoints such as changes in renal function will also be evaluated. The full analysis set, according to the intent-to-treat principle, will be established as the primary analysis population.Ethics and disseminationAll participants will provide informed consent; the study protocol has been approved by the Independent Ethics Committee for each site. This study is designed to investigate the efficacy and safety of RDN using a 5F saline microirrigated RFA. Findings will be shared with participating hospitals, policymakers and the academic community to promote the clinical management of resistant hypertension in China.Trial registrationClinicalTrials.gov ID:NCT02900729; pre-results.
Assessing the efficacy of renal denervation in patients with resistant arterial hypertension

Ocílio Ribeiro Gonçalves,Francinny Alves Kelly,José Guilherme Maia,Artur de Oliveira Macena Lôbo,Vitor Kendi Tsuchiya Sano,Maria Eduarda Cavalcanti Souza,Francisco Cezar Aquino de Moraes,Nimra Farid,Arlindo Bispo da Silva Júnior,Avelar Alves da Silva

DOI: https://doi.org/10.1007/s00059-024-05268-9

2024-09-12

Herz

Abstract:Background Renal denervation (RDN) is an innovative procedure designed to regulate the renal sympathetic nervous system for the control of arterial hypertension (HTN). RDN has emerged as an alternative for patients with resistant HTN. However, the clinical efficacy of RDN remains incompletely elucidated. Methods PubMed, Embase, and Cochrane databases were searched for randomized controlled trials (RCTs) comparing the use of RDN with sham procedure or pharmacological treatment in patients with resistant HTN. Statistical analyses were performed using R Studio 4.3.2 (R Foundation for Statistical Computing, Vienna, Austria). Heterogeneity was examined with the Cochran Q test I 2 statistics. Mean difference (MD) with 95% confidence interval (CI) were pooled across trials. P values of <0.05 were considered statistically significant. The primary outcomes of interest were changes from baseline in systolic blood pressure (SBP), diastolic blood pressure (DBP), and serum creatinine. Results Twenty-one RCTs comprising 3345 patients were included in this meta-analysis, whereby 2004 (59.91%) received renal denervation and 1341 (40.09%) received pharmacological treatment or sham procedure. Follow-up ranged from 2 to 48 months. Compared to control group, RDN significantly reduced SBP (MD −3.53 mm Hg; 95% CI −5.94 to −1.12; p = 0.004; I 2 = 74%) and DBP (MD −1.48 mm Hg; 95% CI −2.56 to −0.40; p = 0.007; I 2 = 51%). Regarding serum creatinine (MD −2.51; 95% CI −7.90 to 2.87; p = 0.36; I 2 = 40%), there was no significant difference between RDN and control groups. Conclusion In this meta-analysis of RCTs of patients with resistant HTN, RDN was associated with a reduction in SBP and DBP compared to sham procedure or pharmacological treatment.

cardiac & cardiovascular systems
Renal denervation for uncontrolled hypertension: a systematic review and meta-analysis examining multiple subgroups

Andrew S.P. Sharp,Alice Sanderson,Neil Hansell,Katie Reddish,Paul Miller,Joe Moss,Roland E. Schmieder,Rachael McCool

DOI: https://doi.org/10.1097/hjh.0000000000003727

IF: 4.9

2024-04-15

Journal of Hypertension

Abstract:This systematic review and meta-analysis was conducted to assess the randomized controlled trial (RCT) evidence available for renal denervation (RDN) in uncontrolled arterial hypertension. Twenty-five RCTs met the eligibility criteria for the systematic review, and 16 RCTs were included in the meta-analysis. The results of the random effects meta-analysis estimated a mean difference of −8.5 mmHg [95% confidence interval (CI) −13.5 to −3.6] for office SBP, −3.6 mmHg (95% CI −5.2 to −2.0) for 24 h SBP and −3.9 mmHg (95% CI −5.6 to −2.2) for ambulatory daytime SBP in favour of RDN compared with control (medication and/or sham-only) at primary follow-up. Similarly favourable results were observed across a range of prespecified subgroup analyses, including treatment-resistant hypertension. This meta-analysis suggests that the use of RDN in uncontrolled hypertension leads to consistent reductions in blood pressure. Reductions appear to be statistically consistent in the presence or absence of medications and in populations resistant to the use of three medications.

peripheral vascular disease
A novel, proof-of-concept radiofrequency renal denervation strategy to improve procedural efficiency: 12-month results from the SPYRAL DYSTAL pilot study

Andrew S P Sharp,David E Kandzari,Raymond R Townsend,Kazuomi Kario,Felix Mahfoud,Michael A Weber,Roland E Schmieder,Konstantinos Tsioufis,Michael Böhm,James W Choi,Minglei Liu,Vanessa DeBruin,David P Lee

DOI: https://doi.org/10.1016/j.carrev.2024.04.005

2024-04-10

Abstract:Background: Catheter-based renal sympathetic denervation (RDN) reduced blood pressure (BP) in multiple randomized sham-controlled trials of patients with uncontrolled hypertension (HTN). We tested proof-of-concept for a more selective treatment strategy, exclusively targeting these areas to improve the efficiency of the procedure. Methods: The SPYRAL DYSTAL Pilot study was designed to mirror the SPYRAL HTN-OFF MED Pivotal study, enabling comparison with a propensity score adjusted active-control group. Patients were antihypertensive medication-free for one month before undergoing BP assessment. Those with office BP of 150-180/>90 mmHg and with an ambulatory systolic BP of 140-170 mmHg were selected to undergo open label treatment, delivering energy only to the distal main renal arteries and first order branches. Patients from DYSTAL were compared with patients who underwent maximized RF RDN treatment in the prior randomized OFF MED trial at 3 months. After 3 months, patients resumed antihypertensive medications as indicated. Safety and efficacy outcomes were assessed post hoc through 12 months. Results: The SPYRAL DYSTAL Pilot study treated 56 HTN patients. Baseline office systolic BP (OSBP) and 24-h ambulatory systolic BP (ASBP) were similar between DYSTAL and OFF MED patient groups. The number of ablations (32.3 ± 8.0 vs 46.6 ± 15.3, p < 0.001), procedure time (67 ± 21 min vs 99 ± 36 min; p < 0.001), and contrast volume (173 ± 77 cc vs 208 ± 96 cc; p = 0.014) were significantly lower with the simplified treatment strategy. OSBP and ASBP changes compared with baseline were -9.0 and -1.4 mmHg at 3 months, -20.3 and -13.9 mmHg at 6 months, and -20.3 and -16.6 mmHg at 12 months, respectively. During the medication up-titration phase, BP reductions among DYSTAL patients were similar to reductions observed in OFF MED through 12 months, with comparable number of drugs (1.4 and 1.5 medications, respectively (P=NS)). Two adverse events related to guidewire placement were reported. Conclusion: In this pilot study, focusing ablation treatment on the distal main and proximal branch renal arteries was performed, resulting in fewer RF lesions, and reduced contrast volume and procedure time. Whether BP reductions are similar between a selective vs. maximized RDN approach requires further prospective study.
EFFECT OF RENAL DENERVATION ON BLOOD PRESSURE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND UNCONTROLLED HYPERTENSION: RESULTS OF A PROSPECTIVE RANDOMIZED SHAM-CONTROLLED STUDY

Roland Schmieder,Dennis Kannenkeril,Michael Böhm,Felix Mahfoud,Lars C. Rump,Johannes Stegbauer,Markus Van Der Giet,Mario Schiffer,Roland Veelken,Michael Uder,Axel Schmid

DOI: https://doi.org/10.1097/01.hjh.0001019616.46093.d5

IF: 4.9

2024-05-01

Journal of Hypertension

Abstract:Objective: The activity of the sympathetic nervous system (SNS) is increased in patients with chronic kidney disease (CKD) and endovascular renal denervation (RDN) offers the opportunity to modulate SNS activity and thereby blood pressure. Hypothesis: In patients with CKD stage 3 and uncontrolled hypertension, endovascular ultrasound-based RDN (uRDN) reduces 24-hour ambulatory BP without adverse safety events. Design and method: In a multicenter prospective randomized clinical trial, following the criteria of a blinded sham-controlled design, patients with CKD stage 3 and uncontrolled hypertension despite prescription of 1-5 antihypertensive medications were enrolled. Patients were randomly allocated to either endovascular uRDN using the ParadiseTM Renal Denervation System (ReCor Medical, Inc., Palo Alto, CA, USA) or a sham procedure restricted to renal angiopgraphy alone. The primary endpoint was the change in mean 24-hour ambulatory systolic BP at 6 months while on stable medication. Secondary endpoints were changes of other 24h ambulatory BP values, office BP and safety parameters of uRDN. Blinding was to be maintained through 6 months. Due to slow recruitment through 2 years, the trial was prematurely stopped. Results: Of 25 randomized patients (mean age 67yrs), 20 subjects had a 6 month visit per protocol. Major cause of CKD was hypertension and/or type-2 diabetes (N=13). There was no difference in clinical characteristics (eGFR, UACR, BMI, HbA1c, comorbidities), pretreatment 24 hour/day/night ambulatory and office BP between the uRDN (N=10) and the sham group (N=10). After 6 months the decrease in 24h(and day) ambulatory diastolic BP was significantly greater in the RDN compared with the sham group (p=0.035 (and 0.030)). Within the uRDN group, 24 hour (and day) ambulatory diastolic BP decreased over time compared to pretreatment values, whereas in the sham group no changes occurred. Systolic ambulatory BP decreased numerically in the uRDN group, but was not significant. No safety concerns related to uRDN emerged. Conclusions: In this randomized sham-controlled blinded study, despite its premature stop leading to a small study cohort, we observed a decrease of diastolic BP after endovascular uRDN and no safety signals in these hypertensive patients with CKD.

peripheral vascular disease
Temperature and humidity dependence of formaldehyde release from selected building materials

C. Netten,C. Shirtliffe,J. Švec

DOI: https://doi.org/10.1007/BF01700238

1989-04-01

Bulletin of Environmental Contamination and Toxicology

Abstract:
Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results from the TARGET BP I Randomized Clinical Trial

David E. Kandzari,Michael A. Weber,Atul Pathak,James P. Zidar,Manish Saxena,Shukri W. David,Roland E. Schmieder,Adam J. Janas,Christoph Langer,Alexandre Persu,Farrell O. Mendelsohn,Koen Ameloot,Malcolm Foster III,Tim A. Fischell,Helen Parise,Felix Mahfoud

DOI: https://doi.org/10.1161/circulationaha.124.069291

IF: 37.8

2024-04-08

Circulation

Abstract:Background: Renal denervation (RDN) has demonstrated clinically relevant reductions in blood pressure among individuals with uncontrolled hypertension despite lifestyle intervention and medications. The safety and effectiveness of alcohol-mediated RDN has not been formally studied in this indication. Methods: TARGET BP I is a prospective, international, sham-controlled, randomized, patient- and assessor-blinded trial investigating the safety and efficacy of alcohol-mediated RDN. Patients with office systolic blood pressure (SBP) ≥150 and ≤180 mmHg, office diastolic BP ≥90 mmHg and mean 24-hour ambulatory SBP ≥135 and ≤170 mmHg, despite prescription of 2-5 antihypertensive medications were enrolled. The primary endpoint was the baseline-adjusted change in mean 24-hour ambulatory systolic BP at 3 months post procedure. Secondary endpoints include mean between-group differences in office and ambulatory BP at additional time points. Results: Among 301 patients randomized 1:1 to RDN or sham control, RDN was associated with a significant reduction in 24-hour ambulatory SBP at 3 months (mean ± standard deviation -10.0 ± 14.2 mmHg versus -6.8 ± 12.1 mmHg, treatment difference -3.2 mmHg, 95% confidence interval [CI] -6.3, 0.0 mmHg; P =0.0487). Subgroup analysis of the primary endpoint revealed no significant interaction across predefined subgroups. At 3 months, the mean change in office SBP was -12.7 ± 18.3 mmHg and -9.7 ± 17.3 mmHg (difference, -3.0, 95% CI -7.0, 1.0; P =0.173), for RDN and sham, respectively. No significant differences in ambulatory or office diastolic BP were observed. Adverse safety events through 6 months were uncommon with 1 instance of accessory renal artery dissection in the RDN group (0.7%). No significant between-group differences in medication changes or patient adherence were identified. Conclusions: Alcohol-mediated RDN was associated with a modest but statistically significant reduction in 24-hour ambulatory systolic BP compared with sham control. No significant differences between groups in office BP or 6-month major adverse events were observed.

cardiac & cardiovascular systems,peripheral vascular disease
Systematic Review and Meta-Analysis of Second-Generation Sham-Controlled Randomized Trials of Renal Denervation Therapy for Patients with Hypertension

Clara Rocha Dantas,Artur De Oliveira Macena Lôbo,Artur Menegaz De Almeida,Francisco Cezar Aquino De Moraes,Vitor Kendi Tsuchiya Sano,Francinny Alves Kelly

DOI: https://doi.org/10.1007/s40292-024-00675-9

2024-10-12

Abstract:Introduction: Renal denervation has been associated with substantial and sustained blood pressure reduction and is considered to serve as an alternative treatment for patients with resistant hypertension. However, the first published SHAM-controlled trial assessing RDN safety and efficacy showed no difference between groups. Aim: We aimed to perform a meta-analysis quantifying the magnitude of blood pressure decrease secondary to renal denervation in patients with resistant hypertension. Methods: Databases were searched for RCTs that compared RDN therapy to SHAM procedure and reported the outcomes of (1) 24-hour ambulatory blood pressure; (2) Office systolic blood pressure; (3) Daytime systolic blood pressure; and (4) Night-time systolic blood pressure. Mean differences with 95% confidence intervals (CIs) were calculated using a random-effects model. Heterogeneity was examined with I² statistics. P values of < 0.05 were considered statistically significant. Statistical analyses were performed using RStudio 4.2.3. Results: Nine studies and 1622 patients were included. The AMBP [MD -3.72 95%CI -5.44, -2.00 p < 0.001; I²=34%] and DSBP [MD -4.10 95%CI -5.84, -2.37 p < 0.001; I²=0%] were significantly reduced in the RDN arm. ODBP [MD -6.04 95%CI -11.31, -0.78 p = 0.024; I²=90%] and NSBP [MD -1.81 95%CI -3.90, 0.27 p = 0.08; I²=0%] did not reach a statistically significant difference between groups. Conclusion: Renal denervation demonstrates greater efficacy in reducing 24-hour ambulatory and daytime systolic blood pressure in patients diagnosed with resistant hypertension.
Studying the Evolution of Online Collective Action: Saudi Arabian Women's 'Oct26Driving' Twitter Campaign

Serpil Yuce,Nitin Agarwal,R. Wigand,M. Lim,Rebecca S. Robinson

DOI: https://doi.org/10.1007/978-3-319-05579-4_50

2014-04-01

Abstract:
12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation

Michel Azizi,Joost Daemen,Melvin D Lobo,Felix Mahfoud,Andrew S P Sharp,Roland E Schmieder,Yale Wang,Manish Saxena,Philipp Lurz,Jeremy Sayer,Michael J Bloch,Jan Basile,Michael A Weber,Lars C Rump,Terry Levy,Marc Sapoval,Kintur Sanghvi,Florian Rader,Naomi D L Fisher,Philippe Gosse,Josephine Abraham,Lisa Claude,Neil C Barman,Candace K McClure,Yuyin Liu,Ajay J Kirtane,RADIANCE-HTN Investigators

DOI: https://doi.org/10.1016/j.jcin.2020.09.054

2020-12-28

Abstract:Objectives: This study reports the 12-month results of the RADIANCE-HTN (A Study of the ReCor Medical Paradise System in Clinical Hypertension) SOLO trial following unblinding of patients at 6 months. Background: The blood pressure (BP)-lowering efficacy and safety of endovascular ultrasound renal denervation (RDN) in the absence (2 months) and presence (6 months) of antihypertensive medications were previously reported. Methods: Patients with daytime ambulatory BP ≥135/85 mm Hg after 4 weeks off medication were randomized to RDN (n = 74) or sham (n = 72) and maintained off medication for 2 months. A standardized medication escalation protocol was instituted between 2 and 5 months (blinded phase). Between 6 and 12 months (unblinded phase), patients received antihypertensive medications at physicians' discretion. Outcomes at 12 months included medication burden, change in daytime ambulatory systolic BP (dASBP) and office or home systolic BP (SBP), visit-to-visit variability in SBP, and safety. Results: Sixty-five of 74 RDN patients and 67 of 72 sham patients had 12-month dASBP measurements. The proportion of patients on ≥2 medications (27.7% vs. 44.8%; p = 0.041), the number of medications (0 vs. 1.4; p = 0.015), and defined daily dose (1.4 vs. 2.2; p = 0.007) were less with RDN versus sham. The decrease in dASBP from baseline in the RDN group (-16.5 ± 12.9 mm Hg) remained stable at 12 months. The RDN versus sham adjusted difference at 12 months was -2.3 mm Hg (95% confidence interval [CI]: -5.9 to 1.3 mm Hg; p = 0.201) for dASBP, -6.3 mm Hg (95% CI: -11.1 to -1.5 mm Hg; p = 0.010) for office SBP, and -3.4 mm Hg (95% CI: -6.9 to 0.1 mm Hg; p = 0.062) for home SBP. Visit-to-visit variability in SBP was smaller in the RDN group. No renal artery injury was detected on computed tomographic or magnetic resonance angiography. Conclusions: Despite unblinding, the BP-lowering effect of RDN was maintained at 12 months with fewer prescribed medications compared with sham.
Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial

Thomas Weber,Siegfried Wassertheurer,Christopher C. Mayer,Bernhard Hametner,Kathrin Danninger,Raymond R. Townsend,Felix Mahfoud,Kazuomi Kario,Martin Fahy,Vanessa DeBruin,Nicole Peterson,Manuela Negoita,Michael A. Weber,David E. Kandzari,Roland E. Schmieder,Konstantinos P. Tsioufis,Ronald K. Binder,Michael Böhm,Thomas WeberSiegfried WassertheurerChristopher C. MayerBernhard HametnerKathrin DanningerRaymond R. TownsendFelix MahfoudKazuomi KarioMartin FahyVanessa DeBruinNicole PetersonManuela NegoitaMichael A. WeberDavid E. KandzariRoland E. SchmiederKonstantinos P. TsioufisRonald K. BinderMichael BöhmCardiology Department,Klinikum Wels-Grieskirchen,Austria (T.W.,K.D.,R.K.B.).AIT - Austrian Institute of Technology,Vienna,Austria (S.W.,C.C.M.,B.H.).Perelman School of Medicine,University of Pennsylvania,Philadelphia (R.R.T.).Klinik für Innere Medizin III,Universitätsklinikum des Saarlandes,Saarland University,Homburg/Saar,Germany (F.M.,M.B.).Jichi Medical University School of Medicine,Tochigi,Japan (K.K.).Medtronic PLC,Santa Rosa,CA (M.F.,V.D.,N.P.,M.N.).SUNY Downstate College of Medicine,Brooklyn,NY (M.A.W.).Piedmont Heart Institute,Atlanta,GA (D.E.K.).Department of Nephrology and Hypertension,University Hospital Erlangen,Friedrich Alexander University Erlangen Nürnberg,Germany (R.E.S.).1st Cardiology Clinic,National and Kapodistrian University of Athens,Hippokration Hospital,Greece (K.P.T.).

DOI: https://doi.org/10.1161/HYPERTENSIONAHA.121.18641

IF: 9.8968

2022-05-20

Hypertension

Abstract:Renal denervation (RDN) lowers blood pressure (BP), but BP response is variable in individual patients. We investigated whether measures of pulsatile hemodynamics, obtained during 24-hour ambulatory BP monitoring, predict BP drop following RDN. From the randomized, sham-controlled SPYRAL HTN-OFF MED pivotal trial, we performed a post hoc analysis of BP waveforms from 111 RDN patients and 111 sham controls, obtained with a brachial cuff-based sphygmomanometer. Waveforms were acquired during ambulatory BP monitoring at diastolic BP level and processed with validated ARCSolver algorithms to derive hemodynamic parameters (augmentation index; augmentation pressure; backward and forward wave amplitude; estimated aortic pulse wave velocity). We investigated the relationship between averaged 24-hour values at baseline and the change in 24-hour BP at 3 months in RDN patients, corrected for observed trends in the sham group. There was a consistent inverse relationship between baseline augmentation index/augmentation pressure/backward wave amplitude/forward wave amplitude/estimated aortic pulse wave velocity and BP response to RDN: the decrease in 24-hour systolic BP/diastolic BP was 7.8/5.9 (augmentation index), 8.0/6.3 (augmentation pressure), 6.7/5.4 (backward wave amplitude), 5.7/4.7 (forward wave amplitude), and 7.8/5.2 (estimated aortic pulse wave velocity) mm Hg greater for patients below versus above the respective median value ( P <0.001 for all comparisons, respectively). Taking augmentation index/augmentation pressure/backward wave amplitude/forward wave amplitude/estimated aortic pulse wave velocity into account, a favorable BP response following RDN, defined as a drop in 24-hour systolic blood pressure of ≥5 mm Hg, could be predicted with an area under the curve of 0.70/0.74/0.70/0.65/0.62 ( P <0.001 for all, respectively). These results suggest that pulsatile hemodynamics, obtained during 24-hour ambulatory BP monitoring, may predict BP response to RDN.

peripheral vascular disease
Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program

Michel Azizi,Andrew S P Sharp,Naomi D L Fisher,Michael A Weber,Melvin D Lobo,Joost Daemen,Philipp Lurz,Felix Mahfoud,Roland E Schmieder,Jan Basile,Michael J Bloch,Manish Saxena,Yale Wang,Kintur Sanghvi,J Stephen Jenkins,Chandan Devireddy,Florian Rader,Philippe Gosse,Lisa Claude,Dimitri A Augustin,Candace K McClure,Ajay J Kirtane,RADIANCE Investigators

DOI: https://doi.org/10.1161/CIRCULATIONAHA.123.066941

IF: 37.8

2024-03-05

Circulation

Abstract:Background: The randomized, sham-controlled RADIANCE-HTN (A Study of the Recor Medical Paradise System in Clinical Hypertension) SOLO, RADIANCE-HTN TRIO, and RADIANCE II (A Study of the Recor Medical Paradise System in Stage II Hypertension) trials independently met their primary end point of a greater reduction in daytime ambulatory systolic blood pressure (SBP) 2 months after ultrasound renal denervation (uRDN) in patients with hypertension. To characterize the longer-term effectiveness and safety of uRDN versus sham at 6 months, after the blinded addition of antihypertensive treatments (AHTs), we pooled individual patient data across these 3 similarly designed trials. Methods: Patients with mild to moderate hypertension who were not on AHT or with hypertension resistant to a standardized combination triple AHT were randomized to uRDN (n=293) versus sham (n=213); they were to remain off of added AHT throughout 2 months of follow-up unless specified blood pressure (BP) criteria were exceeded. In each trial, if monthly home BP was ≥135/85 mm Hg from 2 to 5 months, standardized AHT was sequentially added to target home BP <135/85 mm Hg under blinding to initial treatment assignment. Six-month outcomes included baseline- and AHT-adjusted change in daytime ambulatory, home, and office SBP; change in AHT; and safety. Linear mixed regression models using all BP measurements and change in AHT from baseline through 6 months were used. Results: Patients (70% men) were 54.1±9.3 years of age with a baseline daytime ambulatory/home/office SBP of 150.5±9.8/151.0±12.4/155.5±14.4 mm Hg, respectively. From 2 to 6 months, BP decreased in both groups with AHT titration, but fewer uRDN patients were prescribed AHT (P=0.004), and fewer additional AHT were prescribed to uRDN patients versus sham patients (P=0.001). Whereas the unadjusted between-group difference in daytime ambulatory SBP was similar at 6 months, the baseline and medication-adjusted between-group difference at 6 months was -3.0 mm Hg (95% CI, -5.7, -0.2; P=0.033), in favor of uRDN+AHT. For home and office SBP, the adjusted between-group differences in favor of uRDN+AHT over 6 months were -5.4 mm Hg (-6.8, -4.0; P<0.001) and -5.2 mm Hg (-7.1, -3.3; P<0.001), respectively. There was no heterogeneity between trials. Safety outcomes were few and did not differ between groups. Conclusions: This individual patient-data analysis of 506 patients included in the RADIANCE trials demonstrates the maintenance of BP-lowering efficacy of uRDN versus sham at 6 months, with fewer added AHTs. Registration: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT02649426 and NCT03614260.
Lipschitz Continuity of the Optimal Value via Bounds on the Optimal Set in Linear Semi-Infinite Optimization

M. J. Cánovas,M. López,J. Parra,F. J. Toledo-Moreo

DOI: https://doi.org/10.1287/moor.1060.0198

IF: 2.215

2006-08-01

Mathematics of Operations Research

Abstract:We consider the parametric space of all the linear semi-infinite programming problems with constraint systems having the same index set. Under a certain regularity condition, the so-called well-posedness with respect to the solvability, it is known from Canovas et al. [2] that the optimal value function is Lipschitz continuous around the nominal problem π. In this paper we obtain an explicit Lipschitz constant for such a function in a certain neighborhood of π. We emphasize the fact that both the constant and the size of the neighborhood are exclusively expressed in terms of the nominal problem data, and that they involve the distances to primal and to dual inconsistency. Moreover, a uniform bound for the optimal set is provided. This bound constitutes a key ingredient to derive the Lipschitz constant for the optimal value function.
Favorable effect of renal denervation on elevated renal vascular resistance in patients with resistant hypertension and type 2 diabetes mellitus

Musheg Manukyan,Alla Falkovskaya,Victor Mordovin,Stanislav Pekarskiy,Irina Zyubanova,Ekaterina Solonskaya,Tamara Ryabova,Simzhit Khunkhinova,Anastasia Vtorushina,Sergey Popov

DOI: https://doi.org/10.3389/fcvm.2022.1010546

IF: 3.6

2022-12-15

Frontiers in Cardiovascular Medicine

Abstract:Objective: To assess the effect of renal denervation (RDN) on renal vascular resistance and renal function in patients with drug-resistant hypertension (HTN) and type 2 diabetes mellitus (T2DM). Materials and methods: Fifty-nine patients (mean age 60.3 ± 7.9 years, 25 men) with resistant HTN [mean 24-h ambulatory blood pressure (BP) 158.0 ± 16.3/82.5 ± 12.7 mmHg, systolic/diastolic] and T2DM (mean HbA1c 7.5 ± 1.5%) were included in the single-arm prospective study and underwent RDN. Renal resistive index (RRI) derived from ultrasound Doppler; estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration formula), office and 24-h ambulatory BP were measured at baseline, 6, and 12 months after RDN to evaluate the respective changes in renal vascular resistance, renal function, and BP during treatment. Results: Forty-three patients completed 12 months follow-up. The RRI changed depending on the baseline value. Specifically, the RRI decreased significantly in patients with elevated baseline RRI values ≥ 0.7 { n = 23; −0.024 [95% confidence interval (CI): −0.046, −0.002], p = 0.035} and did not change in those with baseline RRI < 0.7 [ n = 36; 0.024 (95% CI: −0.002, 0.050), p = 0.069]. No significant change was observed in eGFR whereas BP was significantly reduced at 12 months after RDN by −10.9 (95% CI: −16.7, −5.0)/−5.5 (95% CI: −8.7, −2.4) mmHg, systolic/diastolic. No relationship was found between the changes in RRI and BP. Conclusion: Our study shows that RDN can decrease elevated renal vascular resistance (RRI > 0.7) and stabilize kidney function in patients with RHTN and T2DM independently of its BP-lowering effect.

cardiac & cardiovascular systems
Evaluating a dental practice for purchase or associateship.

R. Diecidue

DOI: https://doi.org/10.1016/j.cden.2008.03.001

2008-07-01

Dental Clinics of North America

Abstract:
Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and meta‐analysis of randomized, sham‐controlled, catheter‐based trials

Konstantinos Stavropoulos,Dimitrios Patoulias,Konstantinos Imprialos,Michael Doumas,Alexandra Katsimardou,Kyriakos Dimitriadis,Costas Tsioufis,Vasilios Papademetriou

DOI: https://doi.org/10.1111/jch.13827

2020-02-12

Abstract:Despite the availability of a numerous antihypertensive agents, hypertension treatment and control rates remain low in many countries. The role of the sympathetic nervous system has long been recognized, but recent sham control renal denervation studies demonstrated conflicting results. In this reviewe paper, the authors performed a systematic review and meta‐analysis to examine outcomes of sham‐controlled studies utilizing new technologies and procedures. Six published randomized, sham‐controlled studies were included in this meta‐analysis. Of those, three trials used the first‐generation radiofrequency renal denervation device and technique and the other three used second‐generation devices and techniques. In total, 981 patients with hypertension were randomized in all 6 trials to undergo renal denervation (n = 585) or sham procedure (n = 396). Overall, renal denervation resulted in a decrease of 24‐hours systolic ambulatory blood pressure (ABP) by 3.62 mm Hg (95% CI: −5.28‐−1.96; I2 = 0%), compared to sham procedure (GRADE: low). Renal denervation also reduced daytime systolic ABP by 5.51 mm Hg (95% CI: −7.79‐−3.23; I2 = 0%), compared to sham procedure but not nighttime systolic ABP. Office systolic blood pressure was reduced by 5.47 mm Hg (95% CI −8.10‐−2.84; I2 = 0%), compared to sham control. Further analysis demonstrated that second‐generation devices were effective in reducing blood pressure, whereas the first‐generation devices were not. These results indicate that effective renal denervation can result in significant and clinically meaningful blood pressure reduction. The second‐generation devices provide better renal nerve ablation.

peripheral vascular disease

Clinical trial of a humanized monoclonal anti-IL15Rβ (CD122), in HTLV-1 associated myelopathy/ tropical spastic paraparesis (HAM/TSP)

Impact of Antihypertensive Medication Changes After Renal Denervation Among Different Patient Groups: SPYRAL HTN-ON MED

Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials

Effects of catheter-based renal denervation in hypertension: a systematic review and meta-analysis

Effects of renal denervation on blood pressure in patients with hypertension: a latest systematic review and meta-analysis of randomized sham-controlled trials

Efficacy and Safety of Renal Denervation for Chinese Patients with Resistant Hypertension Using a Microirrigated Catheter: Study Design and Protocol for a Prospective Multicentre Randomised Controlled Trial

Assessing the efficacy of renal denervation in patients with resistant arterial hypertension

Renal denervation for uncontrolled hypertension: a systematic review and meta-analysis examining multiple subgroups

A novel, proof-of-concept radiofrequency renal denervation strategy to improve procedural efficiency: 12-month results from the SPYRAL DYSTAL pilot study

EFFECT OF RENAL DENERVATION ON BLOOD PRESSURE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND UNCONTROLLED HYPERTENSION: RESULTS OF A PROSPECTIVE RANDOMIZED SHAM-CONTROLLED STUDY

Temperature and humidity dependence of formaldehyde release from selected building materials

Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results from the TARGET BP I Randomized Clinical Trial

Systematic Review and Meta-Analysis of Second-Generation Sham-Controlled Randomized Trials of Renal Denervation Therapy for Patients with Hypertension

Studying the Evolution of Online Collective Action: Saudi Arabian Women's 'Oct26Driving' Twitter Campaign

12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation

Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial

Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program

Lipschitz Continuity of the Optimal Value via Bounds on the Optimal Set in Linear Semi-Infinite Optimization

Favorable effect of renal denervation on elevated renal vascular resistance in patients with resistant hypertension and type 2 diabetes mellitus

Evaluating a dental practice for purchase or associateship.

Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and meta‐analysis of randomized, sham‐controlled, catheter‐based trials